Renalytix AI plc (RNLX)

22.32 0.00 (0.00%) At close: 4:00PM EST

Renalytix AI plc

Avon House
19 Stanwell Road Penarth
Cardiff CF64 2EZ
United Kingdom
44 20 3139 2910
http://www.renalytixai.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. James R. McCullough M.B.A.	CEO & Exec. Director	487.72k	N/A	1968
Mr. Fergus Fleming	CTO & Exec. Director	339.95k	N/A	1967
Mr. Thomas H. McLain	Pres & Chief Commercial Officer	N/A	N/A	1959
Mr. Oliver James Sterling III	Chief Financial Officer	N/A	N/A	N/A
Dr. Sally Bowden	Head of Regulatory Affairs & CBO	N/A	N/A	1970
Mr. Baljit Singh	Head of Clinical Operations	N/A	N/A	N/A
Dr. Michael J. Donovan	Chief Medical Officer	N/A	N/A	1954
Salim Hamir	Company Sec.	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.

Corporate Governance

Renalytix AI plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.